Whereas J&J has saved its Ottava robotic beneath wraps, it mentioned the system affords surgical groups the flexibility to adapt to scientific workflows and particular person affected person wants. | Supply: Johnson & Johnson
Johnson & Johnson MedTech this week introduced that it has accomplished the primary instances within the scientific trial for its OTTAVA Robotic Surgical System. The instances mark the primary scientific expertise with the OTTAVA System, it mentioned.
“We’re proud to achieve this necessary milestone in our robotic surgical procedure program,” mentioned Hani Abouhalka, the corporate group chairman of surgical procedure at Johnson & Johnson MedTech.
“OTTAVA is a key innovation in our portfolio of superior surgical applied sciences – all of that are designed to rework the surgical experiences throughout all surgical procedure,” he added. “Our individuals work side-by-side with surgical groups in ORs [operating rooms] around the globe each day to boost the usual of take care of sufferers and ship what’s subsequent in surgical procedure.”
Johnson & Johnson MedTech is a unit of New Brunswick, N.J.-based Johnson & Johnson (J&J), which has greater than 100 years of expertise in drugs and surgical expertise. The corporate mentioned its portfolio consists of robotics, wound closure, adjunctive hemostats, surgical stapling and devices, and digital techniques.
OTTAVA addresses surgical robotics shortcomings
The U.S. Meals and Drug Administration (FDA) granted OTTAVA an investigational system exemption in late 2024. Johnson & Johnson MedTech mentioned it designed the system to advance scientific innovation basically surgical procedure, a major a part of its broader surgical procedure enterprise.
J&J described OTTAVA as “a multi-specialty soft-tissue surgical procedure robotic, supporting a broad vary of procedures throughout affected person anatomy and surgical specialties, together with essentially the most complicated surgical procedures that require a multi-quadrant strategy.” The system’s unified structure, surgical instrumentation constructed on J&J’s Ethicon expertise, and a deliberate connection to the Polyphonic digital ecosystem are meant to satisfy the wants of every affected person’s care and every surgeon’s scientific strategy, the corporate asserted.
Johnson & Johnson MedTech first shared particulars about OTTAVA about 4 years in the past. Since then, it has been comparatively quiet. In October 2021, the corporate pushed again the platform’s improvement timeline by about two years, citing a number of elements.
OTTAVA’s preliminary design included six robotic arms. In November 2023, a J&J replace included adjustments, together with 4 arms to be out there on demand.
Register now so you do not miss out!
Johnson & Johnson MedTech preps for subsequent steps
Dr. Erik Wilson is the chief of minimally invasive and elective common surgical procedure on the College of Texas Well being Houston and the lead investigator for the scientific examine. He carried out a Roux-en-Y gastric-bypass surgical procedure utilizing the OTTAVA Robotic Surgical System at Memorial Hermann-Texas Medical Heart.
“Surgical robotics is on the forefront of innovation in minimally invasive surgical procedure,” mentioned Wilson. “I’m proud to have carried out the primary scientific examine instances with OTTAVA and doubtlessly assist advance the usual in surgical robotics.”
Johnson & Johnson MedTech plans to make use of information from this trial goals to help the surgical system’s skill to carry out quite a lot of procedures. Upon completion of the examine, the corporate plans to submit the OTTAVA system for De Novo authorization within the U.S.
J&J mentioned it is going to goal a sign masking a number of procedures basically surgical procedure throughout the higher stomach. These embody gastric bypass, gastric sleeve, small bowel resection, and hiatal hernia restore.
“As an organization working on the intersection of biology and expertise, scientific proof technology is the core of our innovation packages to advance surgical expertise for sufferers,” mentioned Peter Schulam M.D., Ph.D., and chief scientific officer at Johnson & Johnson MedTech. “Via this scientific examine, we’re proud to be partnering with surgeons to collect proof and help the continued pursuit of scientific examine for the development of robotic-assisted minimally invasive surgical procedure.”
The OTTAVA robotic system is beneath improvement and isn’t but approved to be marketed or offered in any market, famous J&J.
